MIGENIX Reports Second Quarter Fiscal Year 2008 Financi...(tics in both treatment groups are simila...)

Based on a detailed analysis of the data from the Phase II viral kinetics study, the non-responder study and the related extension protocol, there is rationale for increasing the dosage of celgosivir from 400mg per day to 600mg per day to enhance efficacy. We are, therefore, exploring the potential to amend the current viral kinetics study protocol to allow for the increased dose.

All MIGENIX-related clinical trials of celgosivir to date have been conducted in Canada. A US IND application is in the preparation process, with the timing for submission to be determined in conjunction with our plans for the amendment to the viral kinetics study described above, funding considerations, and partnering of the program. MIGENIX has been and continues to be in discussions with potential partners for the further clinical development of celgosivir.

MIGENIX recently received notification that the European Patent Office intends to grant a key patent protecting the use of celgosivir as a treatment for HCV. This follows the issuance of patents in South Korea, New Zealand and South Africa that are also directed to the use of celgosivir for the treatment of HCV and other hepaciviruses. Prosecution of related patent applications, also claiming uses for celgosivir against HCV, continues in other key jurisdictions.

Omiganan (CLS001; topical cationic peptide; treatment of dermatological diseases): Cutanea Life Sciences, Inc., our development and commercialization partner for CLS001, have completed their first Phase II trial designed to evaluate the safety and efficacy of CLS001 in 240 patients with papulopustular rosacea. The results of this randomized, vehicle-controlled, double-blind, multi-center Phase II study, were announced October 17th, 2007. Base
'/>"/>